PMID- 12454820
OWN - NLM
STAT- MEDLINE
DCOM- 20021219
LR  - 20151119
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 33
IP  - 11
DP  - 2002 Nov
TI  - Immunohistochemical profile of high-grade urothelial bladder carcinoma and 
      prostate adenocarcinoma.
PG  - 1136-40
AB  - The differential diagnosis between poorly differentiated prostate adenocarcinoma 
      (PAC) involving the bladder and high-grade urothelial bladder cancer (UC) with 
      prostate extension can be very challenging. The aim of this study is to evaluate 
      the use of a panel of antibodies to distinguish the poorly differentiated forms 
      of these two tumors. We evaluated a series of 40 PAC cases (Gleason's grade >/= 
      8) and 45 (G3) UC cases obtained from transurethral endoscopic resection 
      material. Immunohistochemical analysis was performed using the following 
      antibodies: prostate acid phosphatase (PAP), prostate-specific antigen (PSA), 
      uroplakin III (UP), thrombomodulin (TM), cytokeratin (CK) 7, and CK20. PAC 
      expressed PSA and PAP in 34 and 38 cases, respectively. The sensitivity and 
      specificity of expressing at least 1 marker (PSA+ or PAP+) is 95% and 100%, 
      respectively. All UC cases were negative for both markers. UC expressed UP and TM 
      in 27 and 22 cases, respectively. In addition, 36 of 45 cases stained positively 
      for at least 1 marker (UP + or TM +) with specificity and sensitivity of 80% and 
      100%, respectively. All cases of PAC were negative for both markers. Twenty-eight 
      UC cases were CK7+/CK20 +, and 4 PAC cases stained positively for both markers. 
      On the other hand, 29 PAC cases and 4 UC cases were CK7-/CK20-. We concluded that 
      PSA, PAP, UP, and TM are very useful markers in differentiating poorly 
      differentiated UC from PAC. Finally, when all 4 markers (PAP, PSA, UP, and TM) 
      were negative, CK7 and CK20 appeared of no major use in making the differential 
      diagnosis.
CI  - Copyright 2002, Elsevier Science (USA). All rights reserved.
FAU - Mhawech, Paulette
AU  - Mhawech P
AD  - Office of Biostatistics, The University of Texas Medical Branch at Galveston, 
      Galveston, TX, USA.
FAU - Uchida, Tatsuo
AU  - Uchida T
FAU - Pelte, Marie-Francoise
AU  - Pelte MF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adenocarcinoma/*chemistry/secondary/surgery
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Transitional Cell/*chemistry/secondary/surgery
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Prostatic Neoplasms/*chemistry/pathology/surgery
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Transurethral Resection of Prostate
MH  - Urinary Bladder Neoplasms/*chemistry/secondary/surgery
EDAT- 2002/11/28 04:00
MHDA- 2002/12/20 04:00
CRDT- 2002/11/28 04:00
PHST- 2002/11/28 04:00 [pubmed]
PHST- 2002/12/20 04:00 [medline]
PHST- 2002/11/28 04:00 [entrez]
AID - S0046817702001685 [pii]
AID - 10.1053/hupa.2002.129416 [doi]
PST - ppublish
SO  - Hum Pathol. 2002 Nov;33(11):1136-40. doi: 10.1053/hupa.2002.129416.